ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC). Background: Radiosensitizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results